Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

Human Gene Therapy

Volumn 30, Issue 2, 2019, Pages 168-178

  Foster, Jessica B ^a   Choudhari, Namrata ^a   Perazzelli, Jessica ^a   Storm, Julie ^a   Hofmann, Ted J ^a   Jain, Payal ^a   Storm, Phillip B ^a,b   Pardi, Norbert ^b   Weissman, Drew ^b   Waanders, Angela J ^a   Grupp, Stephan A ^a   Karikó, Katalin ^c   Resnick, Adam C ^a   Barrett, David M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BIONTECH AG   (Germany)

Author keywords

chimeric antigen receptor; immunotherapy; RNA; T cell

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; MESSENGER RNA; NUCLEOSIDE; RIBONUCLEASE III; CD19 ANTIGEN; CD19 MOLECULE, HUMAN;

ANIMAL EXPERIMENT; ANTILEUKEMIC ACTIVITY; ARTICLE; CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; RNA PURIFICATION; SURFACE PROPERTY; ADOPTIVE TRANSFER; ANIMAL; DRUG SCREENING; ELECTROPORATION; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; KNOCKOUT MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD19; CELL LINE, TUMOR; ELECTROPORATION; HUMANS; LEUKEMIA; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; RECEPTORS, CHIMERIC ANTIGEN; RNA, MESSENGER; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85061260151     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2018.145     Document Type: Article

References (54)

1. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother 1997;45:131-136.
2. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90: 720-724.
3. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
4. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009;32:689-702.
5. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-733.
6. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368: 1509-1518.
7. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-1517.
8. Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen eeceptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015;33:1688-1696.
9. Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015;21:3149-3159.
10. Feng K, Guo Y, Dai H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 2016;59:468-479.
11. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-22.
12. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142.
13. Braun CJ, Boztug K, Paruzynski A et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity. Sci Transl Med 2014;6: 227ra233.
14. Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011;22: 1575-1586.
15. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-195.
16. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor Tcell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664-679.
17. Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017;19:867-880.
18. Gust J, Hay KA, Hanafi L-A, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404-1419.
19. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36:133-151.
20. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-851.
21. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013;122:863-871.
22. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013;5: 197ra103.
23. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904-912.
24. Singh N, Liu X, Hulitt J, et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res 2014;2:1059-1070.
25. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70:9053-9061.
26. Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014;65:333-347.
27. Panjwani MK, Smith JB, Schutsky K, et al. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol Ther 2016;24:1602-1614.
28. Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 2017;129:2395-2407.
29. Schutsky K, Song DG, Lynn R, et al. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget 2015;6:28911-28928.
30. Yoon SH, Lee JM, Cho HI, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neuspecific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther 2009; 16:489-497.
31. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov 2014;13:759-780.
32. Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008;16:1833-1840.
33. Anderson BR, Muramatsu H, Jha BK, et al. Nucleoside modifications in RNA limit activation of 2-5-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 2011;39:9329-9338.
34. Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005;23:165-175.
35. Kariko K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011;39:e142.
36. Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010;38:5884-5892.
37. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-3365.
38. Pardi N, Muramatsu H, Weissman D, et al. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 2013;969:29-42.
39. Meis J, Person A, Chin C, et al. Making and using in vitro-synthesized ssRNA for introducing into mammalian cells to induce a biological or biochemical effect. EU patent 2, 798, 064 2016.
40. Barrett DM, Seif AE, Carpenito C, et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 2011;118:e112-117.
41. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008;224:141-165.
42. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3-potential mechanisms of action. Nat Rev Immunol 2015;15:45-56.
43. Huerfano S, Ryabchenko B, Forstova J. Nucleofection of expression vectors induces a robust interferon response and inhibition of cell proliferation. DNA Cell Biol 2013;32:467-479.
44. Anderson BR, Kariko K, Weissman D. Nucleofection induces transient eIF2alpha phosphorylation by GCN2 and PERK. Gene Ther 2013;20:136-142.
45. Zhou X, Di Stasi A, Tey SK, et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 2014;123:3895-3905.
46. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 2017;9.
47. Singh N, Barrett DM, Grupp SA. Roadblocks to success for RNA CARs in solid tumors. Oncoimmunology 2014;3:e962974.
48. Kirschman JL, Bhosle S, Vanover D, et al. Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells. Nucleic Acids Res 2017;45:3113.
49. Tanji H, Ohto U, Shibata T, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat Struct Mol Biol 2015;22:109-115.
50. Zhang Z, Ohto U, Shibata T, et al. Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity 2016;45:737-748.
51. Chen N, Xia P, Li S, et al. RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 2017;69:297-304.
52. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7:618-630.
53. Levy O, Zhao W, Mortensen LJ, et al. mRNAengineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013;122:e23-32.
54. Stadler CR, Bahr-Mahmud H, Celik L, et al. Elimination of large tumors in mice by mRNAencoded bispecific antibodies. Nat Med 2017; 23:815-817.